Kornimate/medical-research-clean huggingface dataset:
the impact of chronic e-cigarette usage on microvascular health

Conditions: E-Cig Use

Summary: the study is focused on investigating the mechanisms involved in microvascular health in subjects that use e-cigarettes frequently. to explore microvascular health, different techniques and compounds. for one of the tests, iontophoresis, the drug's use will be stored and handled as described by the approved ind and non-ids plan.

electronic cigarettes or e-cigarettes have become increasingly popular, due to their promotion as a healthy alternative to traditional tobacco cigarettes. however, there are large discrepancies of knowledge in understanding how these e-cigarettes affect the subjects health and the way their body uses oxygen. the overall goal of this study is to evaluate e-cigarettes usage on subjects health.

Eligibility criteria:
e-cig users arm inclusion criteria: * between 18 and 29 years of age * used e-cigarettes with nicotine (≥3 times/week for ≥6 months) exclusion criteria: * 17 years old and younger or 30 years old or older. * former combustible tobacco user/ former smoker * use of cigarettes for 15 days or more in the past 60 days * use of other tobacco products (cigars, hookah, smokeless), marijuana and/or illicit or prescription drugs weekly or more frequently in the past 60 days * evidence of cardiovascular, pulmonary, renal, hepatic, metabolic, cerebral diseases or sleep disorders * disorder or use of medication that affects cardiopulmonary health * evidence of pregnancy or current nursing non e-cig using arm inclusion - between 18 and 29 years of age exclusion * 17 years old and younger or 30 years old and older * use of cigarettes or other tobacco products more than 50 times in their lifetime. * evidence of cardiovascular, pulmonary, renal, hepatic, metabolic, cerebral diseases or sleep disorders * disorder or use of medication that affects cardiopulmonary health * evidence of pregnancy or current nursing

Keywords: microvascular health
evaluation of optical coherence tomography.

Conditions: Age-Related Macular Degeneration; Choroidal Vessels; Anastomosis

Summary: determination of the sensitivity and specificity of different combinations of imaging techniques (spectral domain optical coherence tomography, fundus photography and fluorescein angiography) used for the diagnosis of choroidal neovessels complicating age -related macular degeneration. this information will help to determine the choice of the most suitable combination for the above diagnosis.

the following combinations will be studied: spectral domain optical coherence tomography (oct) + fundus photography; fluorescein angiography + fundus photography and the combination of all three techniques (oct+ fundus photography + fluorescein angiography).the sensitivity and specificity of the latter combination will be assessed by comparison with the results for this combination reported by several readers. inter- and intra-observer reproducibility of the different combinations will also be studied.

Eligibility criteria:
inclusion criteria: * age\> 50 years * first visit for suspicion of choroidal neo-vessels complicating age related macular degeneration * fundus color photographs , fluorescein angiography and oct prescription exclusion criteria: * age \< 50 years * diabetes * central vein occlusion macular hole epi-retinal membrane retinal detachment macular hemorrhage more than the 1/3 of the lesion * history of macular laser, pdt or intra-vitreal injection

Keywords: age - related macular degeneration optical coherence tomography choroidal neovascularization florescein angiography fundus photographs
comparison of circumferential pulmonary vein isolation and complex pulmonary vein isolation additional linear ablation for recurred atrial fibrillation after previous catheter ablation: prospective randomized trial (rili trial)

Conditions: Recurred Atrial Fibrillation

Summary: the purpose of this study is to compare the clinical outcomes depending on catheter ablation strategy for repeat ablation procedure among the patients with recurred atrial fibrillation after de novo catheter ablation. after randomization, we will conduct circumferential pulmonary vein isolation alone in a group, and additional posterior box isolation in the other group. non-pulmonary vein foci ablation will be done in all patients. we will compare clinical recurrence rate, complication rate, and procedure time, etc.


Eligibility criteria:
inclusion criteria: 1. patients with af aged between 20 and 80 years old. 2. patients possible to anticoagulation and anti arrhythmic drug 3. patients who had undergone de novo ablation procedures based on circumferential pulmonary vein isolation with no additional linear ablations 4. patients undergoing a second ablation procedure due to clinical recurrence resistant to antiarrhythmic drugs with findings of pv reconnections exclusion criteria: 1. structural cardiac disease 2. contraindication to brain perfusion ct 3. catheter ablation history for af, cardiac surgery for af 4. active internal bleeding 5. impossible to anticoagulation or antiarrhythmic drug 6. valvular af ((ma\> gii, mechanical valve, mitral valve raplacement) 7. patients with severe medical disease 8. expected survival \ 60mm

Keywords: recurred atrial fibullation cpvi posterior wall isolation
effects of an evening protein preload on metabolic health in night shift workers (propensity)

Conditions: Type 2 Diabetes; Shift-work Disorder

Summary: this study will compare the effects of a whey protein supplement or a placebo consumed before the evening meal on health outcomes in night shift workers.

participants are assigned in random order to two conditions, for 12 days each. the interventions are 1) a 30g whey protein preload consumed 1-1.5 hr prior to their main evening meal every day for 12 days. no other advice will be given. 2) an identical mixed-nutrient drink matched for caloric content, taste and palatability consumed 1-1.5 hr prior to their main evening meal every day for 12 days(placebo). conditions are separated by a 2-week washout period, during which participants will be encouraged to maintain their habitual diet and physical activity levels. metabolic testing will be performed at baseline, and at the end of both conditions.

Eligibility criteria:
inclusion criteria: * female * night shift workers (with a minimum of 6 months in their current shift work schedule) * 35-65 years * bmi 28.0-35.0 kg/m2; waist circumference \> 80cm * weight stable in the past 6 months exclusion criteria: * those working standard day time hours only, or those who work less than three to four night shifts per fortnight on average * personal history and/or diagnosis of: diabetes, cancer, major psychiatric disorders, liver disease, gastro-intestinal surgery or disease (including malabsorption), eating disorders, anaemia, insomnia or cardiovascular disease, and/or any other condition deemed unstable by the study physician * taking medications known to alter body composition or metabolism, including (but not limited to): any medication used to lower blood glucose or antidiabetic medications (metformin, sulfonylureas, glucagon-like peptide-1 (glp-1) analogues \[i.e. exenatide\], thiazolidinediones or dpp-iv inhibitors \[i.e. 'gliptins'\]), medications affecting weight, appetite or gut motility (i.e. diuretics, domperidone, cisapride, orlistat, phentermine, topiramate) * participants who are taking stable doses (i.e. \> 12 months) of androgenic medications (i.e. testosterone) or ssri's will not be excluded. personal history/diagnosis (self-reported) of diabetes (type 1 or 2), major psychiatric disorders (schizophrenia, major depressive disorder, bipolar disorder, eating disorders), gastrointestinal disorders, haematological disorders (i.e. thalassemia, iron-deficiency anaemia) insomnia, or any other medical condition, deemed unstable by the study physician * pregnant, planning a pregnancy or breastfeeding * those who have lost or gained \>5% of body weight in the last 6 months * those who consume four or more standard drinks on a single occasion at a 'daily or almost daily' occurrence * current smokers of cigarettes/marijuana/e-cigarettes/vaporisers * unable to comprehend the study protocol (i.e. due to english language or cognitive difficulties)
safety and tolerability study of fg-3019 in participants with idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: the main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of fg-3019, a therapeutic antibody designed to block the pro-fibrotic activity of connective tissue growth factor (ctgf). ctgf triggers the production of collagen and fibronectin, which cause scarring and thickening of the lungs. participants will be assigned sequentially to one of the 3 dose group: low, medium, and high fg-3019.


Eligibility criteria:
key inclusion criteria: * have a diagnosis of idiopathic pulmonary fibrosis (ipf) by clinical features and surgical lung biopsy or according to the american thoracic society criteria key exclusion criteria: * have a history of significant exposure to organic or inorganic dust or drugs known to cause pulmonary fibrosis * have interstitial lung disease other than ipf * have pulmonary fibrosis associated with connective tissue disease * have other forms of idiopathic interstitial pneumonia, such as desquamative interstitial pneumonia, acute interstitial pneumonia, nonspecific interstitial pneumonia, or cryptogenic organizing pneumonia * have end-stage ipf (total lung capacity of less than 45% of predicted value) * are listed for lung transplantation at the time of study enrollment * have significant heart problems * are pregnant or lactating (if female) other inclusion and exclusion criteria may apply.

Keywords: idiopathic pulmonary fibrosis ipf pulmonary fibrosis respiratory disease
5-ht3 antagonists (antiemetics) and cardiac safety

Conditions: Adverse Reaction to Other Drugs and Medicines

Summary: 5-ht3 antagonists (ondansetron) are highly effective medications for the treatment of nausea and vomiting. however, these medications also associated with potentially severe and life-threatening cardiac adverse drug reactions (adrs), particularly qt prolongation. data regarding the cardiac safety and inter-individual variability in cardiac effects of ondansetron when used in vulnerable populations such as children and pregnant women are very limited. the results of this study will enable better-informed therapeutic decision-making regarding the use of ondansetron in children and pregnant women, with the overall goal to improve the safety of these commonly used antiemetic medications. furthermore, predictive pharmacogenetic markers of severe 5-ht3 antagonist toxicity could be used to identify patients at risk of cardiac toxicity before the drug is administered.

the specific objectives are to: 1. determine and compare the cardiac safety profile of ondansetron in children, when used for prevention and management of post-operative nausea and vomiting and chemotherapy induced nausea and vomiting. identify clinical factors including pre-existing cardiac conditions or physiological conditions that predispose to ventricular arrhythmias, concomitant cardiotoxic chemotherapy or concomitant volatile anaesthetic agents and investigate their impact on cardiac adverse effects of ondansetron. 2. determine and compare the cardiac safety profile of ondansetron when used in pregnant women or women of a reproductive age for the treatment of hyperemesis gravidarum or post-operative nausea and vomiting. identify clinical factors including pre-existing cardiac conditions or physiological conditions, which predispose to ventricular arrhythmias that may support implementation of risk mitigation actions. 3. identify genetic variants associated with 5-ht3 antagonist-induced prolongation of qt interval.

Eligibility criteria:
inclusion criteria: 1. children 6 months - 18 years of age who are being treated with ondansetron for prevention and management of post-operative nausea and vomiting and chemotherapy-induced nausea and vomiting. 2. pregnant women and women of a reproductive age (18-45 years of age) who are being treated with ondansetron for hyperemesis gravidarum or postoperative nausea and vomiting. exclusion criteria: 1. patients with congenital long qt syndrome. 2. subjects who do not speak and understand english.

Keywords: qt prolongation genomic biomarkers
home-based exercise program during neoadjuvant treatment to improve fatigue and quality of life in early her2-positive and triple-negative breast cancer patients

Conditions: Triple Negative Breast Cancer (TNBC); HER2-Positive Breast Cancer; Early Breast Cancer; Cancer-related Fatigue; Quality of Life (QOL)

Summary: the goal of this trial is to learn if a home-based exercise program (intervention) reduces fatigue and improves quality of life in adult patients with early breast cancer who are proposed for preoperative chemotherapy. conducted at centro hospitalar universitário de santo antónio, porto, portugal. it compares a structured exercise program prescribed by the physical and rehabilitation medicine team to routine counseling for physical activity by the medical oncologist. all participants will: 1. visit the hospital 3 times for physical assessments, at beginning of chemotherapy (t0), at 3-months (t1) and 1 month after surgery (t2) 2. reply to questionnaires of fatigue and quality of life, at t0, t1 and t2 3. adhere to routine medical oncology visits, treatments and exams participants of the intervention-arm will additionally: 1. receive a exercise book, with exercise instructions and calendar 2. have two in-person lessons about the exercise program 3. visit the hospital 1 additional time, to have the second lesson 4. wear a sport bracelet while exercising, to monitor heart rate recruitment began in april 2024, with results to be shared in medical publications and conferences.


Eligibility criteria:
inclusion criteria (must meet all): * adult patients, * any gender, * diagnosed with breast cancer, of her2-positive or triple-negative subtypes, * proposed to neoadjuvant systemic cancer therapy. may be included: patients non-eligible for anthracyclines or anti-her2 therapies; patients with oligometastatic disease proposed for primary/neoadjuvant systemic cancer therapy with intent of radical treatment. exclusion criteria: * patients that do not perform any neoadjuvant antineoplastic therapy, for example because of refusal, impeditive comorbidities, re-staging or other reasons. * contraindications for exercise or impediments to perform the intervention program, because of previous comorbidities or according to medical assessment (e.g. blindness). * patients who are unable to take questionnaires because of language or cognitive barriers (even with small help from a relative or investigator, still cannot answer properly). * luminal-like subtype, with hormonal receptor expression and her2-negative. individual participants will be discontinued from the trial, in agreement with their physician where appropriate, if any health problem arises that will significantly affect their safety to participate in exercise for more than one month or if the participant decides to withdraw their consent.

Keywords: exercise home-based breast cancer fatigue quality of life patient-reported outcomes physical activity neoadjuvant
d68ga-dotatate pet/ct assessment of cardiac sarcoidosis

Conditions: Cardiac Sarcoidosis

Summary: the researchers are trying to determine if 68ga-dotatate pet/ct imaging will have a similar accuracy as 18fdg pet/ct in diagnosing cardiac sarcoidosis and if it will be able to do so without the need for complex patient dietary preparation that is required with 18fdg pet/ct.

prospective study of 15 consecutive patients with suspected or newly diagnosed cardiac sarcoidosis (cs) who are referred for a clinically indicated 18fdg (and 13nh3) pet/ct scan for cardiac sarcoidosis (cs) will be approached to undergo a 68ga-dotatate pet/ct scan. comparison will then be made between the 68ga-dotatate pet/ct and the 18fdg and 13nh3 pet/ct to determine if 68ga-dotatate detects cs.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * referred for clinically indicated 18fdg pet/ct scan for cardiac sarcoidosis (cs) exclusion criteria: * pregnant * unable or unwilling to give consent for 68ga-dotatate pet/ct scan
b-vitamins and polyneuropathy in patients with type 2 diabetes

Conditions: Diabetes Complications

Summary: this case-control study investigated b-vitamin and homocysteine in relation to the presence or the absence of type 2 diabetes and clinical signs of polyneuropathy.

blood samples were collected and clinical investigations were performed at the same time.

Eligibility criteria:
inclusion criteria: * male and female subjects with or without diabetes. exclusion criteria: * usage of supplements containing b-vitamins, methotrexate treatment, cerebral or cardiac events in the last three months * liver or renal dysfunction.
intraoperative lidocaine infusion for postoperative pain management in obese patients

Conditions: Bariatric Surgical Pain

Summary: the primary objective is to assess the feasibility and safety of administering continuous intraoperative lidocaine infusions in adult patients undergoing laparoscopic roux en y gastric bypass (rygb). the secondary objective is to determine if lidocaine administration versus placebo (dextrose administration) (initiated at the time of anesthesia induction and continued until extubation) will reduce postoperative narcotic requirements.


Eligibility criteria:
inclusion criteria: * adult patients between the ages of 18-65 years old * bmi ≥ 40 kg/m2, ≤ 60 kg/m2 * undergoing a primary laparoscopic rygb by dr. murr * agree to be followed 24 hours postoperatively * normal k+ and mg++ serum levels exclusion criteria: * bmi less than 40 kg/m2, \> 60 kg/m2 * laparoscopic rygb surgery performed by a surgeon other than dr. murr * allergy to lidocaine * allergy to hydromorphone or ketorolac * allergy to corn or amide anesthetics * use of (thioridizine) * pregnancy * abnormalities of alt or ast * intra-operative diagnosis of cirrhosis or portal hypertension * intraoperative complications per surgeon * intraoperative extensive adhesions per surgeon * chronic pain syndrome and chronic use of narcotics * severe back pain secondary to degenerative joint disease
efficacy of automated bolus calculation in type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the investigators hypothesize that non-optimal basal-bolus insulin treated patients with type 2 diabetes can achieve better metabolic control by counting carbohydrates with concurrent use of an automated bolus calculator. additionally, the investigators propose that this intervention will lead to improvement in patient related outcomes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes \> 1 year * age 18 years or older * hba1c \> 64 mmol/mol (8.0 %) * treatment with multiple daily insulin injections (basal and prandial insulin) ≥ 6 months * gad-antibody negative * naïve to bolus calculators exclusion criteria: * pregnancy or breast feeding * gastroparesis * severe nephropathy (egfr\<30 ml/min/1,73 m2) * use of sulfonylurea
long-term evaluation of sports activity in patients whose ankle was treated by anatomical reconstruction or arthroscopic repair following chronic lateral instability

Conditions: Ankle Instability

Summary: the goal of this clinical trial is to compare at 5 years the sporting activity of patients whose ankle had been treated by reconstruction or repair following chronic lateral instability. the main question it aims to answer is: what is the long-term sporting activity status of patients whose ankle had been treated by reconstruction or repair following chronic lateral instability ? participants will visit the clinic once every year during 5 years for clinical checkup.


Eligibility criteria:
inclusion criteria: * patient, male or female, aged ≥ 18 years * patient with chronic ankle instability defined by: * a history of trauma including a severe ankle sprain. * clinical symptoms persisting for at least 3 months at the time of inclusion: pain, swelling, sensation of 'giving way', sensation of instability, recurrent sprains; clinical tests (drawer test, varus provocation test) confirming grade iii laxity; imaging results (mri) confirming clinically suspected ligament damage. * patient affiliated to or benefiting from a social security scheme * french-speaking patient who has signed an informed consent form exclusion criteria: * patient with deltoid ligament injury, severe fracture or open trauma * patient with insufficient ligament remnant and/or in too poor a condition to allow broström-type repair. * patient with a symptomatic osteochondral lesion * patient with ankle hyperlaxity (beighton score \> 3) * patient with early ankle arthropathy (takakura arthritis classification ≥ stage 3) * patient with neuromuscular disorders, systemic inflammatory disorders or tumours. * patient requiring surgery on both ankles * patients with a bony deformity of the ankle or foot on the affected side; * patients with professional athlete status * patient already included in another study * protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
study of clinical types and treatment outcomes of pediatric esotropia in sohag university hospital

Conditions: Infantile Esotropia

Summary: strabismus (or squint) is defined as the presence of misalignment between the visual axes of the 2 eyes presenting with deviation of the eyes. strabismus is further subdivided into comitant (if the amount of misalignment between the 2 eyes remained equal in all directions of gaze) and incomitant (if the amount of misalignment varied in different directions of gaze). if the squinting eye was deviated inward, it is termed as a convergent squint or esotropia and if the squinting eye is deviated outward, it is termed as a divergent squint or exotropia. pediatric esotropia may be congenital or acquired. congenital esotropia is a well-defined entity with an onset prior to 6 months of age, characterised by a large stable angle, cross fixation, and a limited potential for binocular single vision. acquired childhood esotropia may be paralytic or non-paralytic. the non-paralytic or concomitant type, which is neither congenital nor secondary to ocular pathology, can be divided into three main groups: (1) accommodative esotropia, which may be fully accommodative, partially accommodative, or accommodative with convergence excess; (2) non-accommodative esotropia; (3) esotropia associated with neurological dysfunction, in particular cerebral palsy and hydrocephalus. the last group of esotropia will be excluded from our study. pediatric strabismus must be treated early to maximize the potential for binocular vision and decrease the risk of amblyopia. treatment goals include good vision in each eye (no amblyopia) and straight eyes (orthotropia). both conditions are necessary to produce stereopsis, which is a third goal. strabismus in children may result in undesirable appearance, amblyopia, impaired stereopsis, diplopia, and negative psychological effect.


Eligibility criteria:
inclusion criteria: 1. infants and children up to the age of 12 years. 2. primary concomitant convergent squint (1ry concomitant esotropia) 3. candidate for surgical correction of squint exclusion criteria: * 1. children with: 1. paralytic squint 2. consecutive esotropia 3. any neurological disorders e.g. hydrocephalus. 4. history of previous squint surgery 5. history of previous other ocular surgery (e.g. congenital cataract \& glaucoma) 2. children who missed follow up.